• Veledimex exhibited dose-related increases in plasma and brain tissue exposure.
• Repeat veledimex dosing shows no accumulation in the brain (48 vs. 312 h).
• Veledimex brain concentration was ~1.7-and 6-fold higher in GL261 mice than in normal mice. No veledimex brain accumulation was observed.
• Dose-response was established, the optimal dose of orally administered veledimex was 450 mg/m 2 total dose p.o. + Ad-RTSmIL-12 1x10 10 vp. • Veledimex p.o. + Ad-RTS-mIL-12 1x10 10 vp improved survival over temozolomide, dexamethasone and bevacizumab.
• These findings support the utility of localized regulatable production as an approach for the treatment of malignant glioma.
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Regulated intratumoral expression of IL-12 promotes activation of tumor-infiltrating lymphocytes to drive a cytotoxic immune response against distant tumors
The Switch Components:
The RTS® gene program includes two receptor protein fusions: VP16-RXR and Gal4-EcR. They form unstable and unproductive heterodimers in the absence of any ligand. 2. The Activator Ligand: An ecdysone analog, diacylhydrazine-based small molecule functions as an activator. In the presence of the ligand, the protein heterodimer changes to a stable conformation and binds to the inducible promoter. 3. The Inducible Promoter: A customizable promoter to which basal transcription proteins are recruited and the target gene is transcribed.
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Veledimex Brain Penetration in Monkeys with Intact Blood Brain Barrier
Summary of plasma and CSF PK parameters of veledimex in cynomolgus monkeys after a single oral dose of 120 mg veledimex in Maisine formulation on Day 1 and after an IV dose of 120 mg/m 2 on Day 8. Veledimex (AL) was administered as a single oral dose of 120 mg (six 20-mg capsules) to a group of 6 cynomolgus monkeys (3/sex). After a 7-day washout, veledimex was administered as a single intravenous (IV) bolus dose of 120 mg/m 2 to the same 6 monkeys. PK parameters are mean values (± SD) based on 6 monkeys (3/sex).
Parameters
Oral IV Plasma Body Weight (kg) 4.1 ± 0.9 4.0 ± 0.9 Dose (mg/m 2 ) 366 ± 82 120 Cmax (ng/mL) 327 ± 142 7462 ± 1241 DN Cmax (ng/mL) 0.9 ± 0.5 62.2 ± 10.3 Tmax (h) 4 ± 1 0.08 ± 0.0 AUC0-t (ng·h/mL) 5887 ± 2203 14145 ± 2983 DN AUC0-t (ng·h/mL) 17.5 ± 8.8 117.9 ± 24.9 AUC0-∞ (ng·h/mL) 5916 ± 2210 14258 ± 3010 t1/2 (h)
25.0 ± 6.1 32.2 ± 5.2
MRT0-t (h)
18.4 ± 5.5 10.1 ± 1.6 CL (mL/h/kg) NA 729 ± 157 Vd (mL/kg) NA 33233 ± 5795 F(%)
14.1 ± 4.9 NA CSF Cmax (ng/mL) 2.07 ± 0. 
